Skip to main content

Table 3 Predictors of development of hepatocellular carcinoma (multivariable Cox regression model)

From: Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens

Variable

HR (95% CI)

P-value

Age, per 10 year increase

1.75 (1.29,2.37)

0.0003

Male sex

1.21 (0.63,2.35)

0.57

Weight, each 5 kg increase

0.83 (0.73,0.96)

0.01

Hypertension

1.01 (0.3,3.42)

0.99

Diabetes

1.46 (0.76,2.79)

0.26

HCV genotype 3 (comparator genotype non-3)

1.42 (0.34,5.99)

0.64

Sustained virologic response

0.35 (0.14,0.85)

0.02

Treatment regimen

 SOF/RBV/PEG-IFN (comparator)

  SOF/RBV

6.75 (0.89,51.1)

0.06

  SOF/DCV/RBV

17.32 (2.14,140.36)

0.01

  SOF/DCV

8.63 (0.53,141.25)

0.13

  1. SOF sofosbuvir, RBV ribavirin, PEG-IFN pegylated interferon, DCV daclatasvir